Special Issue: Immunotheranostics,
Hic Sunt Leones!
Dr. Martin Brechbiel
Dr. Luca Filippi
Cancer Biotherapy and Radiopharmaceuticals is pleased to announce a Special Issue on Immunotheranostics, Hic Sunt Leones!
In 2011, the Food and Drug Administration announced the approval of the first immune checkpoint inhibitor, Ipilumumab, for the treatment of unresectable or metastatic melanoma. Since then, the therapeutic approach consisting in unleashing a pre-existing immune response against the tumor has been extended to many cancer patient subgroups (e.g. lung cancer, lymphoma, hepatocellular carcinoma, etc…) and novel drugs have been implemented in clinical practice. Nevertheless, although the impressive advances achieved in the field, only a minority of patients respond to immunotherapy. In this scenario, molecular imaging with recently introduced radiopharmaceuticals holds the promise to allow an in vivo detection of biomarkers predictive of response, suitable both for patients’ selection and monitoring during treatment, according to the so-called “Theranostic” approach. Furthermore, several efforts have been made to develop combination strategies of immune checkpoint blockade with chemotherapy or radiation therapy.
Potential topics include but are not limited to the following:
• Experimental studies aimed to detect targetable molecular signatures involved in cancer immunoevasion
• Pre-clinical and clinical studies on novel radiopharmaceuticals directed towards immunotherapy-associated targets
• Pre-clinical and clinical studies on novel combination between immunotherapy and other therapeutic strategies (radiation, chemotherapy, targeted therapy)
• Molecular imaging for monitoring immunotherapy response and immune-related adverse events
Please submit your manuscripts by July 31, 2022. Contributions will receive prompt and thorough peer review. Please refer to our Instructions for Authors before submitting your manuscript for consideration.